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Abstract 
Primary adenocarcinoma of the bladder is a
rare tumor. The classification between primary
vesical and urachal is debated. We present the
case of a young female who presented clinico-
pathological features of a metastatic urachal
adenocarcinoma, but the histological result
revealed primary adenocarcinoma of the bladder
contrary to expectancy. To the best of our knowl-
edge this is the first reported case of a metasta-
tic adenocarcinoma of the bladder in a 25 years
old female. This case emphasizes the challenge
for urologists to recognize and manage this
aggressive tumor in the setting described.
Introduction
Pure adenocarcinoma of the bladder is a
rare tumor accounting for 0.5-2% of all bladder
cancers.1 It is classified in primary vesical,
urachal and metastatic. The incidence of pri-
mary adenocarcinoma is greater in areas
where bilharziasis is endemic (5-11.4% of all
bladder tumors) and in adult exstrophy
patients (4%).2,3 It is more common in patients
over 50 years old. The rate of extravesical dis-
ease at diagnosis is higher compared to
urothelial carcinoma because it is often a soli-
tary lesion, has predilection for local invasion
and symptoms are late. Clinical presentation is
similar to others bladder tumors with hema-
turia, suprapubic pain and voiding difficulties
being the most common symptoms. Diagnosis
is made by cystoscopy, urinary cytology and
transurethral resection of the baldder. 
The pathogenesis is different: the urachal
adenocarcinoma arises from the remnant of
the embryonic allantoic stalk, which connects
the umbilicus to the fetal bladder. Conse -
quently, the location of the tumor is always at
the dome of the bladder whereas primary ade-
nocarcinoma of the bladder arises from meta-
plastic changes of unstable urothelium, poten-
tially from any portion of the bladder.4,5 Some
classifications have been suggested. Most
widely used, the Sheldon’s classification has
restrictive criteria. Tumor located at the dome
of the bladder, absence of cystitis glandularis
and cystitis cystica, primary involvement of
muscle or deeper structures, clear demarca-
tion between tumor and normal urothelium,
presence of urachal remnant in association
with the neoplasm and extensions of the
tumor to the space of Retzius are all consid-
ered as necessary criteria to classify a tumor
as an urachal adenocarcinoma.6 Other classifi-
cations use less restrictive criteria considering
a mass arising from the dome of the bladder as
adenocarcinoma of urachus unless a transi-
tion between normal urothelium and adeno-
carcinoma is proved.7
We report a first case of a young female with
a metastatic primary vesical adenocarcinoma
to liver and lung at the time of diagnosis. This
case emphasizes the challenge for urologists
to differentiate urachal and primary adenocar-
cinoma of the bladder preoperatively.
Case Report
A 25 years old female patient without prior
medical history was referred to our hospital for
painless hematuria. Blood tests and physical
examination were normal. At cystoscopy, a
bleeding necrotic mass arising from the bladder
dome was found without any other lesion of the
urothelium. Cytology revealed an adenocarcino-
ma. A computed tomography (CT) scan con-
firmed the mass of the bladder dome extending
to the abdominal wall and showed multiple liver
metastases and one pulmonary metastasis of the
right lower lobe (Figure 1). Urachal adenocarci-
noma was suspected because of the typical local-
ization of the primary tumor. A partial cystecto-
my with en bloc urachectomy up to the umbili-
cus and bilateral pelvic lymph node dissection
was performed. Histological results showed a
muscle-invasive mucinous adenocarcinoma, 7.5
cm in length, without infiltration of urachal rem-
nants (Figure 2). Because of the presence of
glandular cystitis, villous adenoma with intestin-
al metaplasia and absence of tumoral infiltration
of the urachus, the tumor was considered as a
primary vesical adenocarcinoma (Figure 3). Two
abdominal but no pelvic lymph node were invad-
ed. TNM staging was pT3a, pN2, M1, G2-3, R0.
Since the tumor presented histological features
of the digestive tract, a palliative chemotherapy
protocol consisting in bevacizumab, oxaliplatin,
5-fluorouracil and folinic acid was started.
CT scan at 3, 6, 9, 12 and 15 months showed
regression of hepatic metastases, unchanged
pulmonary metastasis and no new metastasis
while treated with 5 fluoro uracil, bevacizumab
and folinic acid.
Discussion
Urachal and primary vesical adenocarcino-
ma are two different tumors, but the impor-
tance of this distinction for the management
and survival is debated. Urachal adenocarci-
noma seems to have better survival rate than
primary vesical adenocarcinoma. Unfortu -
nately, heterogeneity exists in published data,
with regards to treatment modalities (margin
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Figure 1. Computed tomography scan
shows a mass arising from the bladder
dome, compatible with a cancer of the
urachus.
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status, adjuvant therapy, extent of node dis-
section) and patient’s inclusion criteria.
Therefore, careful interpretation of results is
needed.2,7 Because of the anatomical differ-
ence, surgical management is different: radi-
cal cystectomy is performed for primary blad-
der adenocarcinoma whereas partial cystecto-
my with en bloc urachectomy up to the umbili-
cus is considered the gold standard for the
treatment of urachal carcinoma. Staging at
cystectomy is considered the strongest predic-
tor of mortality. Reported 5-year overall sur-
vival rate is poor because the diagnosis is late
when the tumor is often locally advanced and
has spread systemically. Moreover adjuvant
treatment has low efficiency. Adenocarcinoma
is known to be radioresistant and there is no
approved chemotherapy protocol.8-10
The case of this patient is very unusual for
her age and clinical history. The radiological
and clinical features mimicked an adenocarci-
noma of the urachus. The pathologic result
was unexpected. The operation performed was
not the procedure normally performed in pri-
mary adenocarcinoma of the bladder. In this
situation, with the patient’s consent, palliative
chemotherapy was undertaken. After a 15
month follow-up, the patient is free from local
recurrence or new metastasis contrary to
expectancy. Nevertheless since surgical man-
agement is different for urachal and non
urachal adenocarcinoma, we believe that
when a mass at the dome of the bladder is
found, an extensive transurethral resection of
the bladder should be always performed to dif-
ferentiate these two close tumors. 
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Case Report
Figure 2. Gross appearance of the tumor
which measured 7.5 cm of length with no
involvement of the abdominal wall.
Figure 3. Glandular cystitis adjacent to a
villous adenoma with high grade dysplasia
and infiltrating adenocarcinoma.
